Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dextran 40 versus placebo during carotid endarterectomy
ACTRN12609000673246Phase 2Recruiting
- Sponsor
- National Stroke Research Institute
- Start
- Jan 2002
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2 trial of dextran 40 in Carotid artery disease (CAD) (2 arms), sponsored by National Stroke Research Institute. Primary endpoints: Ipsilateral fatal and non-fatal stroke, hemispheric or retinal and Ipsilateral transient ischaemic attack. Started Jan 2002; status: recruiting.
02
Drugs
dextran 40
03
Conditions
Carotid artery disease (CAD)
Beyond the preview
Go deeper on ACTRN12609000673246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000673246.